Epidemiology Venous Pathophysiology Etiology.

Slides:

Advertisements

Similar presentations

8/31/081 TREATMENT OF SMALL VEINS CHRISTI SILER, R.N. SENTARA COSMETIC AND LASER TREATMENT CENTER.

Advertisements

Lower Extremity Venous Disease: Peripheral Venous Insufficiency

 Thrombophlebitis Kyle Christakos, David Cohee, Wade Dowling, Paul James, Levi Street, Stanton Urling.

Multimodal Management of Opioid-Induced Constipation

The Patient Experience With Systemic Lupus Erythematosus

Moderate-to-Severe Asthma Management

New Horizons for SMA.

Clinical Trials in IBD.

New Psoriasis Treatments

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Chronic Hepatitis C Virus Infection

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

This talk will follow the topical structure suggested by the ABP:

Does One Size Fit All in Obesity Management?

Progression After Cancer Immunotherapy in Advanced NSCLC

New Strategies to Prevent CV Events After Hospital Discharge

Current Controversies in Multiple Sclerosis Management

Understanding the Many Faces of Pseudobulbar Affect

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Protecting Patients With Varicose Veins

Neurostimulation for the Management of Medication-Resistant Epilepsy

Case Challenges in Chronic Migraine

Statin Selection in Special Patient Populations: A Case Challenge

Chronic Idiopathic Urticaria

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Multidisciplinary Perspectives on Interstitial Lung Diseases

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Steven T Deak, MD, PhD, FACS Deak Vein NJ Clinic Somerset, NJ

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Gene Therapy: Past, Present, and Future

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

The Different Phases Of Clinical Trials

Impactful Data in TD That Can Guide Treatment Decisions

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

Treatment-Resistant Schizophrenia

Scientific Update.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Program Goals Background: Anticoagulation in Patients With VTE.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

Getting PPG Under Control

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

A study to compare disease-specific quality of life with clinical anatomical and hemodynamic assessments in patients with varicose veins Amanda C. Shepherd,

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Merging the Art and Science of Managing nOH in Clinical Practice

PCSK9 Inhibitors and Real-World Evidence

The Real Burden of Rosacea

Foundations of Asthma.

Advances in Portopulmonary Hypertension

Motor Fluctuations in PD

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Epidemiology

Venous Pathophysiology

Etiology

Risk Factors and Screening Tips

History, Precipitating Factors, and Complications

Patient Assessment

CEAP Classification

Current Treatments

Catheter-based Treatments

Sclerotherapy and Sclerosing Agents

Physician-made Foam for Sclerotherapy

FDA-approved Polidocanol Injectable Foam

VANISH-2 Efficacy

VANISH-2: Symptom Results – VVSymQ™ Scores

Safety Trial for Patients With PFO

Contraindications

Clinical Outcomes

Low DVT Risks of All Options

Varicose Veins Is Cosmetic Treatment Medically Necessary?

Take-Home Messages

Take-Home Messages (cont)

Abbreviations

References

References (cont)